WEINSCHENK, Toni,SINGH, Harpreet,FRITSCHE, Jens,MAHR, Andrea
申请号：
ES11788121
公开号：
ES2592957T3
申请日:
2011.11.22
申请国别(地区):
ES
年份:
2016
代理人:
摘要：
In vitro method for predicting a beneficial effect of an immunotherapy in a cancer patient, which comprises determining the level of apolipoprotein A1 (ApoA1) in a sample obtained from said cancer patient, - in which any level of said marker that at least 10% higher than the median level of said marker in a given population of cancer patients will be indicative of a beneficial effect of an immunotherapy in said cancer patient. - in which said cancer patient is experiencing a cancer selected from the group consisting of renal cell carcinoma (RCC), colorectal cancer (CRC), gastric cancer (GC), melanoma, amyrocytic lung cancer (NSCLC), glioblastoma, and adenocarcinomas of any type； - wherein said sample is selected from the group consisting of whole blood, peripheral blood, or fractions thereof, serum, leukocyte layer, tumor tissue, lymph, urine, bone marrow, EDTA plasma, heparinized plasma, citrate plasma , heparinized whole blood, and frozen samples thereof, such as frozen heparinized whole blood； - wherein said determination comprises at least one method selected from the group consisting of immunoassays, immunoassays with microbeads, multiplex immunoassays, ELISA, micromatrix assays, epigenetic assays, expression analysis, FACS analysis, established methods of hematology, proteomics and spectrometry of masses； - wherein said immunotherapy comprises vaccination with an antitumor vaccine, said vaccination being at least one vaccine comprising at least one immunogenic peptide selected from the group consisting of the peptides conforming to SEQ ID No. 1 to 37； and - in which said beneficial effect is selected from the group consisting of longer overall survival, the appearance of one and / or multiple responses of T lymphocytes against immunotherapy, tumor growth retardation, tumor size decrease or Survival without longer progression.Método in vitro para predecir un efecto beneficioso de una inmunoterapia en un paciente con cáncer, el cual comprende la determinación de
